Italia markets closed

Lantheus Holdings, Inc. (0L8.F)

Frankfurt - Frankfurt Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
61,08+1,36 (+2,28%)
Alla chiusura: 08:04AM CEST
Schermo intero
Chiusura precedente59,72
Aperto61,08
Denaro61,36 x 300000
Lettera61,42 x 300000
Min-Max giorno61,08 - 61,08
Intervallo di 52 settimane46,59 - 91,82
Volume500
Media Volume48
Capitalizzazione4,189B
Beta (5 anni mensile)0,54
Rapporto PE (ttm)14,07
EPS (ttm)4,34
Prossima data utili02 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A32,00
  • GlobeNewswire

    Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting

    BEDFORD, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced PYLARIFY AI data will be presented at the upcoming 2023 European Association of Nuclear Medicine (EANM) Annual Meeting, which will be held September 9-13, 2023 in Vienna, Austria. PYLARIFY AI™ (aPROMI

  • GlobeNewswire

    Lantheus to Present at the Wells Fargo Healthcare Conference

    BEDFORD, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced Paul Blanchfield, President, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday, September 7. To access a li

  • GlobeNewswire

    Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty

    Agreement enhances Lantheus’ strong liquidity position and supports continued pipeline advancement and commercial readinessBEDFORD, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced the divestiture of its RELISTOR (methylnaltrexone bromid